Loading stock data…
Cullinan Therapeutics, Inc. (CGEM)
$18.42+0.02 (+0.11%)
Market ClosedLast close Jun 29
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cullinan Therapeutics, Inc. in the Healthcare sector is trading at $18.42 with a market capitalization of $935M. Wall Street consensus targets $31.55 (11 analysts), implying a +71.3% move over the next 12 months. The stock is currently near its 52-week high of $19.43, remaining 56.8% above its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +71.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$53.70M↑ | -$55.26M↑ | -$55.59M↑ | -$75.80M↓ | -$55.00M |
| Net Income | -$49.66M↑ | -$50.71M↓ | -$50.61M↑ | -$70.06M↓ | -$48.50M |
Peer Comparison
JNJUNHPFE
Fundamentals
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune disease...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$934.78M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.09
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-60.36%
Volume
Today's trading volume
989,968
Recent News
Cullinan Therapeutics (CGEM) Is Up 27.1% After Autoimmune T Cell Engager Data Sparks Immune-Reset Hopes
Earlier in June 2026, Cullinan Therapeutics reported updated Phase 1 data showing CLN-978 and velinotamig produced strong clinical responses and favorable safety in treatment-refractory rheumatoid arthritis and systemic lupus erythematosus. The data, including clinical remission in a rituximab-refractory RA patient and complete renal responses in lupus nephritis, highlight Cullinan’s push to position T cell engagers as off-the-shelf immune-reset therapies across multiple autoimmune...
Prolium Bioscience Sclerosis, Lupus Treatment Studies Advancing
By Karen Roman Prolium Bioscience, Inc. said it dosed its first patient in Phase 1/2 study of PRO-203, a T-cell engager treatment for systemic sclerosis, following the completion of a study in 20 healthy volunteers. The company also completed the last patient and visit in a 26-week study of PRO-203 in treatment-refractory lupus nephritis patients, […] The post Prolium Bioscience Sclerosis, Lupus Treatment Studies Advancing appeared first on ExecEdge.
Will Health Benefits Weakness Drag Elevance's Q1 Earnings?
ELV heads into its April 22 Q1 report with EPS likely down 11.4% as Health Benefits operating income is projected to plunge 13.7% year over year.
Cullinan Therapeutics flags 2026 as “defining year” at Leerink, tees up key CLN-978/CLN-049 data
Cullinan Therapeutics (NASDAQ:CGEM) outlined a milestone-heavy roadmap during a presentation at Leerink Partners’ Annual Healthcare Conference in Miami, with management emphasizing 2026 as a potentially “defining year” driven by multiple clinical readouts across its pipeline. Chief Executive Officer
Cullinan Therapeutics: Q4 Earnings Snapshot
CAMBRIDGE, Mass. AP) — Cullinan Therapeutics, Inc. CGEM) on Tuesday reported a loss of $50.7 million in its fourth quarter.